CGEN

#3025
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
2.63
2.63
Jahresspanne
1.32
3.24
Tagesänderung
-5.40%
Monatliche Änderung
+0.38%
6 month change
+67.52%
Jahresänderung
+69.68%
Vorheriger Schlusskurs
2.7 8
Open
2.6 3
Tief
2.6 3
High
2.6 3
Volumen
11
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotechnologie
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
4.03
Preis-Umsatz-Verhältnis
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Nachrichten